Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Multiple Sclerosis

  Free Subscription


13.07.2026

1 Ann Neurol
1 BMC Neurol
2 Brain
2 J Neuroimmunol
2 J Neurol
3 J Neurol Sci
6 Mult Scler
1 Nat Med
1 Proc Natl Acad Sci U S A


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Neurol

  1. REINDERS EM, Masot-Llima A, Otero-Romero S, Carvajal R, et al
    Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.
    Ann Neurol. 2026 Jul 6. doi: 10.1002/ana.78275.
    PubMed         Abstract available


    BMC Neurol

  2. ALSALLOUM T, Alsamman H, Alkerdi R, Alassad G, et al
    Diagnostic overshadowing in primary progressive multiple sclerosis with coexisting tethered cord syndrome and long-standing urological dysfunction: a case report and literature review.
    BMC Neurol. 2026 Jul 6. doi: 10.1186/s12883-026-05161.
    PubMed         Abstract available


    Brain

  3. SANDGREN S, Leppert D, Kuhle J
    Propionic acid and neurofilament light chain in multiple sclerosis.
    Brain. 2026 Jul 6:awag192. doi: 10.1093.
    PubMed        

  4. MOSER T, Hitzl W, Lerda-Casaccia T, Unterhofer M, et al
    Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial.
    Brain. 2026;149:2286-94.
    PubMed         Abstract available


    J Neuroimmunol

  5. LOPES LMF, Hygino J, Cafasso MOS, Sacramento PM, et al
    Absence of PD-1 expression on T(FH) and T(FC) cell subsets correlates with severity of multiple sclerosis.
    J Neuroimmunol. 2026;419:579012.
    PubMed         Abstract available

  6. GLUSCEVIC S, Koc ER, Klisic A, Ziemssen T, et al
    Peripheral redox biomarkers in multiple sclerosis: associations with phenotype, cognition, and fatigue.
    J Neuroimmunol. 2026;419:579018.
    PubMed         Abstract available


    J Neurol

  7. INOJOSA H, Masanneck L, Akgun K, Hagler R, et al
    From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis.
    J Neurol. 2026;273:454.
    PubMed         Abstract available

  8. FILIPPI M, Grimaldi LME, Brescia Morra V, Conte A, et al
    Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.
    J Neurol. 2026;273:452.
    PubMed         Abstract available


    J Neurol Sci

  9. FRANCE-RATCLIFFE M, Harrison SL, Verma LA, Abdul-Rahim AH, et al
    Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS.
    J Neurol Sci. 2026;488:126007.
    PubMed         Abstract available

  10. ELISA L, Maria P, Lorenza N, Caterina L, et al
    Unmasking the invisible: Correlates and impact of cognitive complaints in MS.
    J Neurol Sci. 2026;488:126022.
    PubMed         Abstract available

  11. BOLANOS BERMUDEZ IA, Noguera V, Barrios Castellar DA, Mora JC, et al
    Mental health comorbidity and multiple sclerosis outcomes: Clarifying progression through longitudinal, imaging, and equity-focused markers.
    J Neurol Sci. 2026;489:126091.
    PubMed        


    Mult Scler

  12. SCALFARI A, Bianchi A
    Preventing frailty in multiple sclerosis is a realistic goal - No.
    Mult Scler. 2026 Jul 9:13524585261466107. doi: 10.1177/13524585261466107.
    PubMed        

  13. LOREFICE L, Zivadinov R
    Preventing frailty in multiple sclerosis is a realistic goal-Commentary.
    Mult Scler. 2026 Jul 9:13524585261466101. doi: 10.1177/13524585261466101.
    PubMed        

  14. ZANOTTO T, Sosnoff JJ
    Preventing frailty in multiple sclerosis is a realistic goal: Yes.
    Mult Scler. 2026 Jul 9:13524585261466113. doi: 10.1177/13524585261466113.
    PubMed        

  15. LIN TY, Bacchetti A, McCormack B, Moussa H, et al
    Association of epiretinal membranes with disability in people with multiple sclerosis.
    Mult Scler. 2026 Jul 6:13524585261446834. doi: 10.1177/13524585261446834.
    PubMed         Abstract available

  16. SYC-MAZUREK S, Chen JJ
    Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?
    Mult Scler. 2026 Jul 6:13524585261464504. doi: 10.1177/13524585261464504.
    PubMed        

  17. PAOLICELLI D, Lucisano G, Manni A, Iaffaldano P, et al
    Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).
    Mult Scler. 2026 Jul 4:13524585261457317. doi: 10.1177/13524585261457317.
    PubMed         Abstract available


    Nat Med

  18. OH J, Barkhof F, Bar-Or A, Ciccarrelli O, et al
    Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.
    Nat Med. 2026 Jul 9. doi: 10.1038/s41591-026-04490.
    PubMed        


    Proc Natl Acad Sci U S A

  19. DE VIRGILIIS F, Barnoud C, He W, Zeng Q, et al
    Circadian screening of neutrophils identifies therapeutic targets in multiple sclerosis.
    Proc Natl Acad Sci U S A. 2026;123:e2536812123.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum